Menu Search
Equities

Intellia Therapeutics Inc

38I:DEU

Intellia Therapeutics Inc

Actions
  • Price (EUR)9.69
  • Today's Change0.564 / 6.18%
  • Shares traded6.89k
  • 1 Year change-64.71%
  • Beta--
Data delayed at least 15 minutes, as of Mar 07 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Intellia Therapeutics Inc had net income fall 7.86% from a loss of 481.19m to a larger loss of 519.02m despite a 59.55% increase in revenues from 36.28m to 57.88m.
Gross margin--
Net profit margin-896.77%
Operating margin-923.10%
Return on assets-41.66%
Return on equity-54.00%
Return on investment-45.81%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Intellia Therapeutics Inc fell by 37.57m. Cash Flow from Financing totalled 185.75m or 320.93% of revenues. In addition the company used 348.88m for operations while cash from investing totalled 125.57m.
Cash flow per share-5.15
Price/Cash flow per share--
Book value per share8.55
Tangible book value per share8.55
More ▼

Balance sheet in USDView more

Intellia Therapeutics Inc uses little or no debt in its capital structure.
Current ratio5.77
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.